Literature DB >> 16816886

Leptin levels in Henoch-Schönlein purpura.

Yuksel Aliyazicioglu1, Ozan Ozkaya, Husamettin Yakut, Ismail Islek, Muhlise Alvur.   

Abstract

The objective of this paper is to assess the possible role of nitric oxide (NO) and leptin in Henoch-Schönlein purpura (HSP). We investigated the serum leptin and total nitrite levels in 22 children with HSP in the acute phase and after remission and in 20 age- and sex-matched healthy control. Serum leptin levels (nanograms per milliliter; median, min-max) were statistically higher in the acute phase (12.9, 9.1-19.5) than those in the remission phase (6.1, 3.7-10.5, p<0.001) and in the control group (4.9, 3.8-7.5, p<0.001). Also, serum nitrite levels (micromole per liter; median, min-max) were higher in children in the acute phase (45.0, 32.0-60.0) compared to those in remission phase (30.5, 23.0-48.0) and in the control group (29.5, 18.0-38.0) (p<0.001, p<0.001, respectively). There was a positive correlation between serum leptin and total nitrite levels (r=0.65, p<0.001). We have demonstrated that serum leptin and NO levels were increased during the acute phase in children with HSP, and returned to normal levels in remission. We suggest that leptin and NO may have a role in the immunoinflammatory process of HSP, especially in the acute phase. Further studies are needed to clearly establish the roles of leptin and NO in the pathogenesis of HSP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16816886     DOI: 10.1007/s10067-006-0363-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  27 in total

1.  Influence of intravenously administered leptin on nitric oxide production, renal hemodynamics and renal function in the rat.

Authors:  Jerzy Bełtowski; Jerzy Jochem; Grazyna Wójcicka; Krystyna Zwirska-Korczala
Journal:  Regul Pept       Date:  2004-08-15

Review 2.  Nitric oxide and the pathogenesis of heart muscle disease.

Authors:  A J de Belder; M W Radomski; J F Martin; S Moncada
Journal:  Eur J Clin Invest       Date:  1995-01       Impact factor: 4.686

3.  Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction.

Authors:  D L Granger; R R Taintor; K S Boockvar; J B Hibbs
Journal:  Methods Enzymol       Date:  1996       Impact factor: 1.600

Review 4.  Nitric oxide and glomerulonephritis.

Authors:  Victoria Cattell
Journal:  Kidney Int       Date:  2002-03       Impact factor: 10.612

5.  Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus.

Authors:  E Svenungsson; M Andersson; L Brundin; R van Vollenhoven; M Khademi; A Tarkowski; D Greitz; M Dahlström; I Lundberg; L Klareskog; T Olsson
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

6.  Nitric oxide: a cytotoxic activated macrophage effector molecule.

Authors:  J B Hibbs; R R Taintor; Z Vavrin; E M Rachlin
Journal:  Biochem Biophys Res Commun       Date:  1988-11-30       Impact factor: 3.575

7.  Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes.

Authors:  T G Kirchgessner; K T Uysal; S M Wiesbrock; M W Marino; G S Hotamisligil
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

8.  Nitric oxide in Henoch-Schönlein purpura.

Authors:  Oğuz Söylemezoğlu; Ozan Ozkaya; Deniz Erbaş; Nermin Akkök; Necla Buyan; Enver Hasanoğlu
Journal:  Scand J Rheumatol       Date:  2002       Impact factor: 3.641

9.  Increased urinary nitrite excretion in children with minimal change nephrotic syndrome.

Authors:  H Trachtman; B Gauthier; R Frank; S Futterweit; A Goldstein; J Tomczak
Journal:  J Pediatr       Date:  1996-02       Impact factor: 4.406

Review 10.  Molecular studies of leptin: implications for renal disease.

Authors:  P Stenvinkel; F Lönnqvist; M Schalling
Journal:  Nephrol Dial Transplant       Date:  1999-05       Impact factor: 5.992

View more
  7 in total

1.  Serum and urine nitric oxide levels in children with Henoch-Schonlein purpura during activity and remission: a study from North India.

Authors:  Vikas Mahajan; Surjit Singh; Madhu Khullar; Ranjana W Minz
Journal:  Rheumatol Int       Date:  2008-11-29       Impact factor: 2.631

2.  Inducible nitric oxide synthase gene polymorphisms are associated with a risk of nephritis in Henoch-Schönlein purpura children.

Authors:  Jue Jiang; Wuqiong Duan; Xu Shang; Hua Wang; Ya Gao; Peijun Tian; Qi Zhou
Journal:  Eur J Pediatr       Date:  2017-06-08       Impact factor: 3.183

3.  Cerebral vasculitis in a child with Henoch-Schönlein purpura and familial Mediterranean fever.

Authors:  Ozan Ozkaya; Kenan Bek; Neşe Alaca; Meltem Ceyhan; Yonca Açikgöz; Haydar Ali Taşdemir
Journal:  Clin Rheumatol       Date:  2007-01-19       Impact factor: 2.980

4.  Serum level of advanced oxidation protein products (AOPPs) in patients with Henoch-Schonlein purpura and its relationship with aberrant glycosylation of IgA1 and Cosmc mRNA expression.

Authors:  Qiang Liu; Yun Yang; Shealinna Ge; JianLi Huo; DaHu Wang; YaoHui Ma; ShaoMin Shi; Ding Luo; JieHua Deng; CuiMin Ren; BingShen Guo
Journal:  Int J Dermatol       Date:  2019-06-27       Impact factor: 2.736

5.  Serum leptin, a potential predictor of long-term angiographic progression in Takayasu's arteritis.

Authors:  Lili Ma; Wensu Yu; Xiaomin Dai; Mengmeng Yin; Yujiao Wang; Ying Sun; Xiufang Kong; Xiaomeng Cui; Sifan Wu; Zongfei Ji; Lingying Ma; Huiyong Chen; Jiang Lin; Lindi Jiang
Journal:  Int J Rheum Dis       Date:  2019-10-09       Impact factor: 2.454

6.  Ghrelin and adipokines as circulating markers of disease activity in patients with Takayasu arteritis.

Authors:  Hatice Yilmaz; Vedat Gerdan; Didem Kozaci; Dilek Solmaz; Servet Akar; Gercek Can; Aytac Gulcu; Yigit Goktay; Ismail Sari; Merih Birlik; Nurullah Akkoc; Fatos Onen
Journal:  Arthritis Res Ther       Date:  2012-12-21       Impact factor: 5.156

7.  ANCA-associated Vasculitis in a Case of Congenital Leptin Deficiency.

Authors:  Atiya Yaseen; Shagufta Rather; Faizan Yunus; Iffat Hassan
Journal:  Indian J Dermatol       Date:  2018 May-Jun       Impact factor: 1.494

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.